TSE:REUN Reunion Neuroscience (REUN) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free REUN Stock Alerts Add Compare Share Share Today's Range N/A50-Day RangeC$1.42▼C$1.4652-Week Range N/AVolume339 shsAverage Volume12,447 shsMarket CapitalizationC$16.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Reunion Neuroscience alerts: Email Address Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Reunion Neuroscience Stock (TSE:REUN)Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.Read More Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide REUN Stock News HeadlinesApril 16, 2024 | americanbankingnews.comReunion Neuroscience (TSE:REUN) Shares Down 2.7% August 5, 2023 | theglobeandmail.comClosing Bell: Reunion Neuroscience Inc flat on Wednesday (REUN)April 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. August 1, 2023 | finance.yahoo.comReunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of ArrangementJuly 16, 2023 | theglobeandmail.comReunion Neuroscience: Stocks Overvalued by Analyst Consensus on TSX (REUN)July 14, 2023 | finance.yahoo.comReunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of ArrangementJuly 13, 2023 | marketwatch.comReunion Neuroscience Shareholders Agree to $13.1M Sale to MPM BioImpactJuly 13, 2023 | finance.yahoo.comReunion Neuroscience Inc. Shareholders Approve Proposed Plan of ArrangementApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. June 2, 2023 | finance.yahoo.comWhat's Going On With Reunion Neuroscience Stock TodayJune 1, 2023 | msn.comReunion Neuroscience Explodes Higher on Buyout DealJune 1, 2023 | msn.comReunion Neuroscience Announces $13.1M Take-Private Transaction With Biotech Investment FirmJune 1, 2023 | technews.tmcnet.comREUN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Reunion Neuroscience Inc. Is Fair to ShareholdersApril 25, 2023 | benzinga.comReunion Neuroscience Enters Compliance Period, Struggles To Remain NASDAQ ListedMarch 27, 2023 | finance.yahoo.comReunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual MeetingMarch 3, 2023 | foxnews.com‘Jeopardy!” contestant tells Mayim Bialik that she was his childhood crush: ‘You haven’t aged a day!’February 22, 2023 | msn.comThe first-ever ‘Jeopardy!’ High School Reunion is packed with New EnglandersFebruary 14, 2023 | markets.businessinsider.comEF Hutton Reaffirms Their Buy Rating on Reunion Neuroscience (REUN)February 2, 2023 | finance.yahoo.comReunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ETJanuary 17, 2023 | finance.yahoo.comReunion Neuroscience (TSE:REUN) investors are sitting on a loss of 74% if they invested a year agoJanuary 9, 2023 | finance.yahoo.comReunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104See More Headlines Receive REUN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reunion Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:REUN CUSIPN/A CIKN/A Webwww.fieldtriphealth.com Phone888-519-6016FaxN/AEmployees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($3.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-38,100,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-86.35% Return on Assets-26.50% Debt Debt-to-Equity RatioN/A Current Ratio3.52 Quick RatioN/A Sales & Book Value Annual SalesC$4.86 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueC$1.82 per share Price / BookN/AMiscellaneous Outstanding Shares11,720,000Free FloatN/AMarket CapC$16.64 million OptionableNot Optionable Beta4.20 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Hannan Fleiman (Age 42)Co-Founder & Non-Independent Director Comp: $282.64kDr. Nathan Bryson B.Sc. (Age 59)Ph.D., Chief Science Officer Comp: $411.37kMr. Gregory T. Mayes Esq. (Age 54)J.D., Pres, CEO & Director Mr. Edward F. Smith CPA (Age 52)Chief Financial Officer Mr. Curtis WeberGen. CounselMr. Stephan CoteHead of QualityDr. Robert Alexander M.D.Chief Medical Officer & Sr. AdvisorMore ExecutivesKey CompetitorsSirona BiochemCVE:SBMResverlogixTSE:RVXKane BiotechCVE:KNENeptune Wellness SolutionsTSE:NEPTAntibe TherapeuticsTSE:ATEView All Competitors REUN Stock Analysis - Frequently Asked Questions How do I buy shares of Reunion Neuroscience? Shares of REUN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:REUN) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsMan Who Predicted 2008: “This Will be Worse.”AltimetryJim Cramer’s “The Biggest Drug Ever”Behind the MarketsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reunion Neuroscience Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
